These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 26631611)

  • 1. Toward Personalized Lymphoma Immunotherapy: Identification of Common Driver Mutations Recognized by Patient CD8+ T Cells.
    Nielsen JS; Sedgwick CG; Shahid A; Zong Z; Brumme ZL; Yu S; Liu L; Kroeger DR; Treon SP; Connors JM; Gascoyne RD; Berry BR; Marra MA; Morin RD; Macpherson N; Nelson BH
    Clin Cancer Res; 2016 May; 22(9):2226-36. PubMed ID: 26631611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. It's a long way to the top (if you want to personalize immunotherapy).
    Haebe S; Weigert O
    J Immunother Cancer; 2017; 5():6. PubMed ID: 28116089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes.
    Wang J; Press OW; Lindgren CG; Greenberg P; Riddell S; Qian X; Laugen C; Raubitschek A; Forman SJ; Jensen MC
    Mol Ther; 2004 Apr; 9(4):577-86. PubMed ID: 15093188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation.
    Green MR; Kihira S; Liu CL; Nair RV; Salari R; Gentles AJ; Irish J; Stehr H; Vicente-Dueñas C; Romero-Camarero I; Sanchez-Garcia I; Plevritis SK; Arber DA; Batzoglou S; Levy R; Alizadeh AA
    Proc Natl Acad Sci U S A; 2015 Mar; 112(10):E1116-25. PubMed ID: 25713363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma.
    Nielsen JS; Chang AR; Wick DA; Sedgwick CG; Zong Z; Mungall AJ; Martin SD; Kinloch NN; Ott-Langer S; Brumme ZL; Treon SP; Connors JM; Gascoyne RD; Webb JR; Berry BR; Morin RD; Macpherson N; Nelson BH
    Oncoimmunology; 2017; 6(7):e1321184. PubMed ID: 28811957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.
    Pastore A; Jurinovic V; Kridel R; Hoster E; Staiger AM; Szczepanowski M; Pott C; Kopp N; Murakami M; Horn H; Leich E; Moccia AA; Mottok A; Sunkavalli A; Van Hummelen P; Ducar M; Ennishi D; Shulha HP; Hother C; Connors JM; Sehn LH; Dreyling M; Neuberg D; Möller P; Feller AC; Hansmann ML; Stein H; Rosenwald A; Ott G; Klapper W; Unterhalt M; Hiddemann W; Gascoyne RD; Weinstock DM; Weigert O
    Lancet Oncol; 2015 Sep; 16(9):1111-1122. PubMed ID: 26256760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profiling of potential driver mutations in sarcomas by targeted next generation sequencing.
    Andersson C; Fagman H; Hansson M; Enlund F
    Cancer Genet; 2016 Apr; 209(4):154-60. PubMed ID: 26987750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen.
    Neelapu SS; Baskar S; Gause BL; Kobrin CB; Watson TM; Frye AR; Pennington R; Harvey L; Jaffe ES; Robb RJ; Popescu MC; Kwak LW
    Clin Cancer Res; 2004 Dec; 10(24):8309-17. PubMed ID: 15623607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection and Tracking of NY-ESO-1-Specific CD8+ T Cells by High-Throughput T Cell Receptor β (TCRB) Gene Rearrangements Sequencing in a Peptide-Vaccinated Patient.
    Miyai M; Eikawa S; Hosoi A; Iino T; Matsushita H; Isobe M; Uenaka A; Udono H; Nakajima J; Nakayama E; Kakimi K
    PLoS One; 2015; 10(8):e0136086. PubMed ID: 26291626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrent Mutations in the MTOR Regulator RRAGC in Follicular Lymphoma.
    Ying ZX; Jin M; Peterson LF; Bernard D; Saiya-Cork K; Yildiz M; Wang S; Kaminski MS; Chang AE; Klionsky DJ; Malek SN
    Clin Cancer Res; 2016 Nov; 22(21):5383-5393. PubMed ID: 27267853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma.
    Wahlin BE; Sander B; Christensson B; Kimby E
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):388-97. PubMed ID: 17255259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. gammadelta T lymphocytes count is normal and expandable in peripheral blood of patients with follicular lymphoma, whereas it is decreased in tumor lymph nodes compared with inflammatory lymph nodes.
    Braza MS; Caraux A; Rousset T; Lafaye de Micheaux S; Sicard H; Squiban P; Costes V; Klein B; Rossi JF
    J Immunol; 2010 Jan; 184(1):134-40. PubMed ID: 19949101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Impact of Hybrid Capture-Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer.
    Rozenblum AB; Ilouze M; Dudnik E; Dvir A; Soussan-Gutman L; Geva S; Peled N
    J Thorac Oncol; 2017 Feb; 12(2):258-268. PubMed ID: 27865871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of somatic mutations in human gastrointestinal cancers.
    Tran E; Ahmadzadeh M; Lu YC; Gros A; Turcotte S; Robbins PF; Gartner JJ; Zheng Z; Li YF; Ray S; Wunderlich JR; Somerville RP; Rosenberg SA
    Science; 2015 Dec; 350(6266):1387-90. PubMed ID: 26516200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations.
    Abrams SI; Khleif SN; Bergmann-Leitner ES; Kantor JA; Chung Y; Hamilton JM; Schlom J
    Cell Immunol; 1997 Dec; 182(2):137-51. PubMed ID: 9514698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous lymphoma vaccines induce human T cell responses against multiple, unique epitopes.
    Baskar S; Kobrin CB; Kwak LW
    J Clin Invest; 2004 May; 113(10):1498-510. PubMed ID: 15146248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 2 trial of immunotherapy with mitumprotimut-T (Id-KLH) and GM-CSF following rituximab in follicular B-cell lymphoma.
    Koç ON; Redfern C; Wiernik PH; Rosenfelt F; Winter JN; Carter WD; Gold DP; Stewart ME; Ghalie RG; Bender JF
    J Immunother; 2010; 33(2):178-84. PubMed ID: 20145546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1--positive, regulatory, cytotoxic, and helper T cells and macrophages.
    Wahlin BE; Aggarwal M; Montes-Moreno S; Gonzalez LF; Roncador G; Sanchez-Verde L; Christensson B; Sander B; Kimby E
    Clin Cancer Res; 2010 Jan; 16(2):637-50. PubMed ID: 20068089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surveillance of the tumor mutanome by T cells during progression from primary to recurrent ovarian cancer.
    Wick DA; Webb JR; Nielsen JS; Martin SD; Kroeger DR; Milne K; Castellarin M; Twumasi-Boateng K; Watson PH; Holt RA; Nelson BH
    Clin Cancer Res; 2014 Mar; 20(5):1125-34. PubMed ID: 24323902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of autologous cytotoxic CD4+ T clones in a human model of B-cell non-Hodgkin follicular lymphoma.
    Mi JQ; Manches O; Wang J; Perron P; Weisbuch S; Marche PN; Renversez JC; Bensa JC; Sotto JJ; Cahn JY; Leroux D; Bonnefoix T
    Br J Haematol; 2006 Nov; 135(3):324-35. PubMed ID: 16984392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.